RxDoctor Payments DataLook up a doctor →

Rajesh Jain, MD

Gastroenterology · Lakewood, CONPI 1811922339

Payments from drug & device makers

$707,591in general payments, 2019–2025

Across 1,061 payments — averaging $666.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$220K
  • Bristol Myers Squibb$131K
  • Phathom Pharmaceuticals, Inc.$96K
  • Lilly USA, LLC$82K
  • Johnson & Johnson$50K
  • F. Hoffmann-la Roche AG$39K
  • plus $89K from 40 others
$1,308in research payments, 2019–2025

Across 13 payments — averaging $100.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Consulting fees$30,60813%
  • Speaking & faculty fees$151,21663%
  • Travel & lodging$28,16412%
  • Food & beverage$28,29012%
  • Education$4090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$707,591 in reported general payments places this provider in the 95th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$74,134
Medicare patients
371
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid12$124,099
LinzessLinaclotide25$13,395
VoqueznaVonoprazan Fumarate17$11,823
Pantoprazole Sodium313$2,184
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag11$1,399
Esomeprazole Magnesium18$1,193
Omeprazole55$1,028
Ursodiol11$750
Sulfasalazine14$429
Famotidine16$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$346$124,09912 claims
AbbVieLinzess$220,401$13,39525 claims
Phathom Pharmaceuticals, Inc.Voquezna$95,825$11,82317 claims
Braintree Laboratories, Inc.Suflave$88$1,39911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Lakewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →